Pharmacokinetics of tenofovir during pregnancy and postpartum

B. M. Best*, S. Burchett, H. Li, A. Stek, C. Hu, J. Wang, E. Hawkins, M. Byroads, D. H. Watts, E. Smith, C. V. Fletcher, E. V. Capparelli, M. Mirochnick, Francesca Aweeka, Nantasak Chotivanich, Tim Roy Cressey, Lisa M. Frenkel, Amita Gupta, Amy Jennings, Gonzague JourdainRegis Kreitchmann, Rita Patel, Kittipong Rungruengthanakit, David Shapiro, Pra ornsuda Sukrakanchana, Andrea Kovacs, James Homans, La Shonda Spencer, Francoise Kramer, Shelley Buschur, Hunter Hammill, Mary E. Paul, Chivon McMullen-Jackson, Ann Melvin, Corry Venema-Weiss, Jenna Lane, Jane Hitti, Katherine Knapp, E. T. Edwin Thorpe, L. Jill Utech, Nina Sublette, Diane Wara, Deborah Cohan, Nicole Tilton, Mary Elizabeth Vachon, Mirza Mahboobullah Baig, Murli Udharam Purswani, Jenny Gutierrez, Helen Cejtin, Julie Schmidt, for the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Tenofovir disoproxil fumarate (TDF) is increasingly used in the highly active antiretroviral therapy (HAART) regimens of pregnant women, but limited data exist on the pregnancy pharmacokinetics of chronically dosed TDF. This study described tenofovir pharmacokinetics during pregnancy and postpartum. Methods: International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s is a prospective, nonblinded pharmacokinetic study of HIV-infected pregnant women that included a cohort receiving 300mg TDF once daily. Steady-state 24-hour pharmacokinetic profiles were measured at the second and third trimesters, postpartum, and in maternal and umbilical cord samples collected at delivery. Tenofovir was measured by liquid chromatography-mass spectrometry (LC-MS). The target area under the concentration versus time curve from time 0 to 24h post dose (AUC) was ≥1.99μg h/mL (nonpregnant historical control 10th percentile). Results: The median tenofovir AUC was decreased during the second (1.9μg h/mL) and third (2.4μg h/mL; P=0.005) trimesters versus postpartum (3.0μg h/mL). Tenofovir AUC exceeded the target for two of four women (50%) in the second trimester, 27 of 37 women [73%; 95% confidence interval (CI) 56%, 86%] in the third trimester, and 27 of 32 women (84%; 95% CI 67%, 95%) postpartum (P>0.05). Median second/third-trimester troughs were lower (39/54ng/mL) than postpartum (61ng/mL). Median third-trimester weight was greater for subjects below the target AUC versus those above the target (97.9 versus 74.2kg, respectively; P=0.006). The median ratio of cord blood to maternal concentrations was 0.88. No infants were HIV infected. Conclusions: This study found lower tenofovir AUC and troughs during pregnancy. Transplacental passage with chronic TDF use during pregnancy was high. Standard TDF doses appear to be appropriate for most HIV-infected pregnant women but therapeutic drug monitoring with dose adjustment should be considered in pregnant women with high weight (>90kg) or inadequate HIV RNA response.

Original languageEnglish (US)
Pages (from-to)502-511
Number of pages10
JournalHIV Medicine
Issue number8
StatePublished - Sep 1 2015


  • Antiretrovirals
  • HIV
  • Pregnancy
  • Prevention of perinatal transmission
  • Tenofovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy


Dive into the research topics of 'Pharmacokinetics of tenofovir during pregnancy and postpartum'. Together they form a unique fingerprint.

Cite this